In addition, as for all biotherapeutics, an adequate system is necessary to ensure specific identification of the SBPs (i.e. traceability). The NRA shall provide a legal framework for proper pharmacovigilance surveillance and ensure the ability to identify any biotherapeutics marketed in their territory which is the subject of adverse reaction reports. This implies that an adverse reaction report for any biotherapeutic should include, in addition to the International Nonproprietary Names (INN)12, other important indicators such as proprietary (brand) name, manufacturer’s name, lot number and country of origin.